Twist Bioscience(NASDAQ) TWST

Twist Bioscience makes custom DNA for scientists and drug companies. It uses silicon chips to write genetic code quickly and cheaply. These products help researchers find medicines and improve medical tests.

Building Blocks of Biology

• NGS Applications: Tools for next-generation sequencing (NGS), which is the process of reading DNA to find genetic markers; represented 52% of revenue in the nine-month period ended June 30, 2026.
• DNA Synthesis and Protein Solutions: Custom DNA fragments, genes, and proteins used for research and drug discovery; accounted for 48% of revenue in the nine-month period ended June 30, 2026.
• Synthetic Genes: Individual sequences of genetic material manufactured for customers in agriculture, chemicals, and academic research.

Scaling the Platform

• Acquired a 6.24% ownership stake in Invenra Inc. in February 2026 to access a proprietary platform for antibody discovery.
• Established a $200 million equity program in June 2026 to allow for the potential sale of common stock.
• Sold the DNA digital data storage business in fiscal year 2025 to focus on core synthesis and sequencing products.
• Expanded the South San Francisco headquarters in November 2025 to consolidate multiple office locations.

What Makes Twist Different?

Twist utilizes a proprietary silicon-based platform to manufacture DNA with higher precision and lower costs than older chemical methods. The company serves over 3,800 customers annually through a direct sales team and an online store for ordering custom genetic materials.

Tracking the Numbers

• Total revenues rose 20% to $332.8 million during the nine-month period ended June 30, 2026.
• Gross margin reached 52.1% in the nine months ended June 30, 2026, up from 50.5% in the prior year period.
• Net loss was $109.6 million for the nine-month period ended June 30, 2026.
• Cash, cash equivalents, and short-term investments totaled $166.8 million as of June 30, 2026.
• Accumulated deficit reached $1,429.2 million as of June 30, 2026.

Evolution of Synthetic DNA

Twist has transitioned from a DNA manufacturer into a provider of integrated biological tools for healthcare and industrial research. The company continues to prioritize revenue growth and manufacturing scale while managing significant historical losses.